Search for other papers by Susanne Neumann in
Google Scholar
PubMed
Search for other papers by Christine C. Krieger in
Google Scholar
PubMed
Search for other papers by Marvin C. Gershengorn in
Google Scholar
PubMed
molecule IGF-1R inhibitor, linsitinib, inhibited HA stimulation by TSH [ 6 ]; (2) the high-potency phase of the biphasic dose response of HA secretion stimulated by a monoclonal TSHR-stimulating antibody (TSAb) M22, which was derived from a patient with
Search for other papers by Gerd Krause in
Google Scholar
PubMed
Search for other papers by Anja Eckstein in
Google Scholar
PubMed
Search for other papers by Ralf Schülein in
Google Scholar
PubMed
]. Pathological activation of the TSHR by TSHR-stimulating autoimmune antibodies (TSAb) leads to the uncontrolled production of thyroid hormones T3 and T4 in the thyroid causing hyperthyroidism in Graves’ disease (GD) [ 5 ]. The TSAb binds to the TSHR at a similar
Search for other papers by Tanja Diana in
Google Scholar
PubMed
Search for other papers by Hans-Peter Holthoff in
Google Scholar
PubMed
Search for other papers by Julia Fassbender in
Google Scholar
PubMed
Search for other papers by Christian Wüster in
Google Scholar
PubMed
Search for other papers by Michael Kanitz in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Search for other papers by Martin Ungerer in
Google Scholar
PubMed
, 28 ]. The cut-off is at 34% inhibition. All sera were measured in duplicate and data were reported as mean values. Bioassay for Stimulating TSHR Antibodies Levels of serum TSHR-stimulating antibodies (TSAb) were measured with an FDA
Search for other papers by Tanja Diana in
Google Scholar
PubMed
Search for other papers by Paul D. Olivo in
Google Scholar
PubMed
Search for other papers by Yie-Hwa Chang in
Google Scholar
PubMed
Search for other papers by Christian Wüster in
Google Scholar
PubMed
Search for other papers by Michael Kanitz in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
receptors per cell. In contrast, studies with the stimulating human monoclonal antibody (M22) [ 39 ] allow for comparison of the signal transduction of the two TSH-R. When stimulating with M22 MAb, the CHO-MC4 cells produced higher levels of cAMP and
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
either via competitive-binding immunoassays or with bioassays [ 4 ]. Antibody-binding assays only report the presence or absence of TSHR-Ab and their concentrations, but do not indicate their functional activity. Bioassays, in contrast, indicate whether
Search for other papers by Tanja Diana in
Google Scholar
PubMed
Search for other papers by Christian Wüster in
Google Scholar
PubMed
Search for other papers by Paul D. Olivo in
Google Scholar
PubMed
Search for other papers by Angelica Unterrainer in
Google Scholar
PubMed
Search for other papers by Jochem König in
Google Scholar
PubMed
Search for other papers by Michael Kanitz in
Google Scholar
PubMed
Search for other papers by Artur Bossowski in
Google Scholar
PubMed
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Introduction Antibodies (Ab) to the thyroid-stimulating hormone receptor (TSHR) may mimic [ 1 - 3 ] or block [ 4 ] the action of TSH or be functionally neutral [ 5 ]. TSHR stimulating Ab (TSAb) are responsible for many of the clinical
Department of Oto-Rhino-Laryngology – Head and Neck Surgery, University Hospital Essen, Essen, Germany
Search for other papers by Anke Schlüter in
Google Scholar
PubMed
Department of Ophthalmology, University Hospital Essen, Essen, Germany
Search for other papers by Anja K. Eckstein in
Google Scholar
PubMed
Search for other papers by Alexandra Brenzel in
Google Scholar
PubMed
Search for other papers by Mareike Horstmann in
Google Scholar
PubMed
Search for other papers by Stephan Lang in
Google Scholar
PubMed
Search for other papers by Utta Berchner-Pfannschmidt in
Google Scholar
PubMed
Search for other papers by J. Paul Banga in
Google Scholar
PubMed
Search for other papers by Salvador Diaz-Cano in
Google Scholar
PubMed
hyperthyroidism with resultant hypothyroidism. Thyroid-stimulating antibodies, the proximal cause of Graves hyperthyroidism, arise from the breakdown in self-tolerance to the TSHR [ 11 ]. The pathophysiological relationship between TSHR, TPO, and Tg autoantibodies
Search for other papers by C. Daumerie in
Google Scholar
PubMed
Search for other papers by A. Boschi in
Google Scholar
PubMed
Search for other papers by P. Perros in
Google Scholar
PubMed
, and the demonstration of a relationship between the level of antibodies to the TSHR (TSHR-Ab) and the development of GO indicates that autoimmune reactions against the TSHR may be a prime cause of GO. TSHR-Ab are present in the serum of the majority of
Search for other papers by Naohiro Araki in
Google Scholar
PubMed
Search for other papers by Mitsuru Iida in
Google Scholar
PubMed
Search for other papers by Nobuyuki Amino in
Google Scholar
PubMed
Search for other papers by Shinji Morita in
Google Scholar
PubMed
Search for other papers by Akane Ide in
Google Scholar
PubMed
Search for other papers by Eijun Nishihara in
Google Scholar
PubMed
Search for other papers by Mitsuru Ito in
Google Scholar
PubMed
Search for other papers by Jun Saito in
Google Scholar
PubMed
Search for other papers by Tetsuo Nishikawa in
Google Scholar
PubMed
Search for other papers by Kiyonori Katsuragi in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
Hashimoto's thyroiditis [ 3 ]. The amount of TSHR antibodies can be measured with competitive binding assays, the so-called thyrotropin-binding inhibitory immunoglobulin/TSHR antibodies (TRAb) assay, using either labeled thyroid-stimulating hormone (TSH
Search for other papers by R. Paschke in
Google Scholar
PubMed
Search for other papers by M. Niedziela in
Google Scholar
PubMed
Search for other papers by B. Vaidya in
Google Scholar
PubMed
Search for other papers by L. Persani in
Google Scholar
PubMed
Search for other papers by B. Rapoport in
Google Scholar
PubMed
Search for other papers by J. Leclere in
Google Scholar
PubMed
characterized by: (1) A positive family history of non-autoimmune hyperthyroidism with dominant inheritance. (2) An absence of clinical (ophthalmopathy or dermopathy) or other stigmata of autoimmunity [TSHR antibodies, thyroid peroxidase (TPO) antibodies